Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma

被引:101
作者
Kuittinen, T
Nousiainen, T
Halonen, P
Mahlamäki, E
Jantunen, E
机构
[1] Kuopio Univ Hosp, Dept Med, Kuopio, Finland
[2] Univ Kuopio, Ctr Comp, FIN-70211 Kuopio, Finland
[3] Kuopio Univ Hosp, Dept Clin Chem, SF-70210 Kuopio, Finland
关键词
non-Hodgkin's lymphoma; mobilisation failure; predictive factors;
D O I
10.1038/sj.bmt.1704466
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Factors affecting progenitor cell mobilisation in patients with non-Hodgkin's lymphoma (NHL) are incompletely understood. We have analysed factors predicting mobilisation failure in 97 consecutive patients with NHL ( 59 males, 38 females; median age 49 years) who received mobilisation with intermediate-dose CY ( 4 g/m(2)) followed by G-CSF. The histology included large cell B ( N = 50), mantle cell ( N = 16), follicular ( N = 16) an d other NHL ( N = 15). The disease status was 1CR/PR/primary refractory in 66 patients and >1 CR/PR in 31 patients. The minimum criterion for successful mobilisation was the collection of greater than or equal to1.5 x 10(6)/ kg CD34(+) cells. In all, 18 patients (19%) failed to reach this threshold. In univariate analysis, premobilisation factors associated with mobilisation failure included BM involvement at the time of diagnosis ( P = 0.001) or prior to mobilisation ( P = 0.001) and low platelet count just prior to mobilisation ( P = 0.001). In multivariate analysis, only BM involvement at diagnosis ( P = 0.004) and platelet count just prior to mobilisation ( P = 0.01) were associated with mobilisation failure. A mathematical model based on these two factors and presented in the form of a receiver operating characteristics curve showed a sensitivity of 0.71 and a specificity of 0.77 in the prediction of mobilisation failure. Patients at a high risk of mobilisation failure may benefit from novel approaches.
引用
收藏
页码:907 / 912
页数:6
相关论文
共 27 条
[1]  
Akard L, 2000, J CLIN ONCOL, V18, P3063, DOI 10.1200/JCO.2000.18.16.3063
[2]   FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS [J].
BENSINGER, W ;
APPELBAUM, F ;
ROWLEY, S ;
STORB, R ;
SANDERS, J ;
LILLEBY, K ;
GOOLEY, T ;
DEMIRER, T ;
SCHIFFMAN, K ;
WEAVER, C ;
CLIFT, R ;
CHAUNCEY, T ;
KLARNET, J ;
MONTGOMERY, P ;
PETERSDORF, S ;
WEIDEN, P ;
WITHERSPOON, R ;
BUCKNER, CD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2547-2555
[3]   Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system [J].
Clark, RE ;
Brammer, CG .
BONE MARROW TRANSPLANTATION, 1998, 22 (09) :859-863
[4]   PERIPHERAL-BLOOD STEM-CELL MOBILIZATION USING HIGH-DOSE CYCLOPHOSPHAMIDE AND G-CSF IN PRETREATED PATIENTS WITH LYMPHOMA [J].
CRAIG, JIO ;
ANTHONY, RS ;
STEWART, A ;
THOMSON, EB ;
GILLON, J ;
PARKER, AC .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 85 (01) :210-212
[5]   Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system [J].
Drake, M ;
Ranaghan, L ;
Morris, TCM ;
Nolan, L ;
Desai, ZR ;
Irvine, AE ;
Jordan, A ;
Magill, K ;
Price, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (03) :745-749
[6]   It's moving day: Factors affecting peripheral blood stem mobilization and strategies for improvement [J].
Fruehauf, S ;
Seggewiss, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (03) :360-375
[7]   Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy [J].
Glaspy, JA .
BONE MARROW TRANSPLANTATION, 1999, 23 (Suppl 2) :S21-S27
[8]   Hematopoietic stem cell transplantation activity in Europe 1999 [J].
Gratwohl, A ;
Passweg, J ;
Baldomero, H ;
Urbano-Ispizua, A .
BONE MARROW TRANSPLANTATION, 2001, 27 (09) :899-916
[9]   Current trends in hematopoietic stem cell transplantation in Europe [J].
Gratwohl, A ;
Baldomero, H ;
Horisberger, B ;
Schmid, C ;
Passweg, J ;
Urbano-Ispizua, A .
BLOOD, 2002, 100 (07) :2374-2386
[10]  
HARRIS NL, 1994, BLOOD, V84, P1361